Company intelligence / Profile preview

Nanjing Calmhome Cell & Gene Engineering Institute

Nanjing, Jiangsu Sheng, China

Ownership: Private
Development stage: Other

Overview

Multiple clinical trials underway (5 identified by May 2025), including Phase 1 trials for CAR-T products targeting hematological malignancies and mesothelin-positive pancreatic cancer. No commercialization or Phase 2/3 assets yet; all clinical results are early-stage and focused on safety and early efficacy endpoints.

Therapeutic areas: OncologyInfectious DiseasesHematologyOtherNeurologyEndocrinology
Modalities: CAR-T cell therapyUniversal CAR-T cell therapyFusion proteinMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

CHT102

Partnerships

Tianjin Medical University Cancer Institute and Hospital

Beyond the preview

Go deeper on Nanjing Calmhome Cell & Gene Engineering Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Calmhome Cell & Gene Engineering Institute.

Explore the full profile